|Bid||86.56 x 1300|
|Ask||86.57 x 2200|
|Day's range||85.04 - 87.28|
|52-week range||69.18 - 99.84|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||16.48|
|Forward dividend & yield||3.09 (3.66%)|
|Ex-dividend date||03 Mar 2020|
|1y target est||102.67|
Q1 GDP, Durable Goods and, of course, Initial Jobless Claims all hit the tape an hour before the bell, along with a new COVID-19 vaccine candidate and an executive order on social media.
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
The hydroxychloroquine debate is far from over, as the drug gets qualified support from others deeply involved in the war against the coronavirus.
The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.
When Mac Holmes noticed a lump in the middle of his chest it took him a year to mention it to his physician. The 55-year-old, who flew packages for FedEx after a 28-year career with the US Air Force, appeared a picture of middle-aged vigour. Days later he was diagnosed with breast cancer, a disease that has spread to his bones.
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
Global Blood Therapeutics (NASDAQ: GBT) plans to report its first quarter earnings on Wednesday, May 6. Importantly, investors will see the first full quarter of sales for Oxbryta, the company's recently approved drug for adults and children age 12 and older with sickle cell disease. The Food and Drug Administration (FDA) approved Oxbryta on Nov. 25., three months before the FDA's Priority Review action date for the decision.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.
Novartis (NVS) reports strong results for the first quarter, driven by solid performance from key drugs and forward purchasing due to COVID-19.
The U.S. death toll and COVID-19 cases climbed, as arguments flared over coronavirus treatments and the path to restarting the economy.
Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.
Investors will focus on regular top and bottom-line numbers along with the impact of the coronavirus pandemic on its outlook when Novartis (NVS) reports first-quarter 2020 results.
Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.
Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.